Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    ZN-c3

A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04516447
Recruitment Status : Recruiting
First Posted : August 18, 2020
Last Update Posted : March 23, 2021
Sponsor:
Information provided by (Responsible Party):
K-Group Beta

Brief Summary:
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

Condition or disease Intervention/treatment Phase
Solid Tumor Epithelial Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer Drug: ZN-c3 Drug: Carboplatin Drug: Pegylated liposomal doxorubicin Phase 1

Detailed Description:
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3. This study consists of 2 cohorts in participants with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. One cohort will test a combination of ZN-c3 and pegylated liposomal doxorubicin (PLD), and the other cohort will test a combination of ZN-c3 and carboplatin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
Actual Study Start Date : October 26, 2020
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : January 1, 2023


Arm Intervention/treatment
Experimental: Combination with carboplatin
Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles (± 3 days), and (2) carboplatin 5 mg/mL*min intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle (± 3 days)
Drug: ZN-c3
Investigational drug
Other Name: Study drug

Drug: Carboplatin
Carboplatin is an approved drug

Experimental: Combination with PLD
Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles (± 3 days), and (2) PLD 50 mg/m^2 intravenously over 60 minutes every 4 weeks, on Day 1 of each 28-day cycle
Drug: ZN-c3
Investigational drug
Other Name: Study drug

Drug: Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin (PLD) is an approved drug




Primary Outcome Measures :
  1. To investigate the safety and tolerability of ZN-c3 in combination with PLD and with carboplatin, respectively [ Time Frame: Through completion, approximately 24 months ]
    Incidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

  2. To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of ZN-c3 in combination with PLD and with carboplatin, respectively [ Time Frame: Through Cycle 1 (cycle is 28 days for PLD, and 21 days for carboplatin) ]
    Incidence and severity of dose-limiting toxicities (DLTs) in DLT-evaluable subjects during Cycle 1


Secondary Outcome Measures :
  1. To obtain estimates of clinical activity by determining the objective response rate (ORR) of ZN-c3 in combination with PLD and with carboplatin, respectively [ Time Frame: Through completion, approximately 24 months ]
    Objective response rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors RECIST version 1.1

  2. To obtain estimates of clinical activity by determining the duration of response (DOR) of ZN-c3 in combination with PLD and with carboplatin, respectively [ Time Frame: Through completion, approximately 24 months ]
    Duration of response (DOR) as defined by Response Evaluation Criteria in Solid Tumors RECIST version 1.1

  3. To obtain estimates of clinical activity by determining the progression-free survival (PFS) of ZN-c3 in combination with PLD and with carboplatin, respectively [ Time Frame: Through completion, approximately 24 months ]
    Progression-free survival (PFS) as defined by RECIST version 1.1 and clinical criteria

  4. To obtain estimates of clinical activity by determining the time to CA125 progression of ZN-c3 in combination with PLD and with carboplatin, respectively [ Time Frame: Through completion, approximately 24 months ]
    Time to CA125 progression according to the Gynecologic Cancer Intergroup (GCIG) criteria

  5. To investigate the plasma pharmacokinetics (PK) of ZN-c3 in combination with PLD and with carboplatin, respectively [ Time Frame: Through completion, approximately 24 months ]
    Plasma PK parameters of ZN-c3 (and its potential metabolites as applicable)


Other Outcome Measures:
  1. To investigate the pharmacodynamics of ZN-c3 on the biological activity of γH2AX [ Time Frame: Through completion, approximately 24 months ]
    Biological activity in pre- versus post-dose tumor tissue, hair follicle samples and peripheral blood mononuclear cell (PBMC) samples of γH2AX

  2. To investigate the pharmacodynamics of ZN-c3 on the biological activity of phosphorylated cyclin-dependent kinase 1 (phospho-CDK1) [ Time Frame: Through completion, approximately 24 months ]
    Biological activity in pre- versus post-dose tumor tissue, hair follicle samples and peripheral blood mononuclear cell (PBMC) samples of phosphorylated cyclin-dependent kinase 1 (phospho-CDK1)

  3. To investigate the pharmacodynamics of ZN-c3 on the biological activity of Ki-67 [ Time Frame: Through completion, approximately 24 months ]
    Biological activity in pre- versus post-dose tumor tissue, hair follicle samples and peripheral blood mononuclear cell (PBMC) samples of Ki-67

  4. To investigate the pharmacodynamics of ZN-c3 on Baseline Cyclin E expression [ Time Frame: Through completion, approximately 24 months ]
    Including, but not limited to, Baseline Cyclin E expression in pre-dose tumor tissue

  5. To investigate the pharmacodynamics of ZN-c3 on molecular determinants of sensitivity to ZN-c3 [ Time Frame: Through completion, approximately 24 months ]
    Molecular determinants of sensitivity to ZN-c3 including but not limited to Baseline DNA Damage Repair (DDR) gene mutations, deletions, copy number variations or indices of genetic instability in either tumor tissue or cell-free DNA (cfDNA)

  6. To characterize the PK of ZN-c3 in tumor tissue [ Time Frame: At Cycle 1 Day 1 and Cycle 2 Day 1 (pre-dose) (each cycle is 28 days for PLD, and 21 days for carboplatin) ]
    ZN-c3 concentrations (and its potential metabolites as applicable) in tumor tissue



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of written informed consent prior to initiation of any study-related procedures that are not considered standard of care.
  • Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of informed consent.
  • ECOG performance status ≤ 2.
  • Histologically or cytologically confirmed high-grade serous epithelial ovarian carcinoma, fallopian tube, or peritoneal carcinoma.
  • Subjects must have received 1 or 2 prior chemotherapy regimens.
  • The disease must be platinum-resistant, i.e., the Platinum-Free Interval (PFI) must have been < 6 months. Platinum refractory disease, i.e., PD during first-line platinum-based therapy is allowed.
  • Measurable disease per RECIST version 1.1.
  • Adequate hematologic and organ function as defined by the following criteria:

    1. ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily administration of filgrastim/sargramostim or within 3 weeks after administration of pegfilgrastim.
    2. Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days after transfusion of platelets.
    3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastases, AST and ALT ≤ 5 x ULN.
    4. Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.
    5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.
  • Female subjects of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-hCG) test and agree to use an effective method of contraception per institutional standard.
  • Left ventricular ejection fraction (LVEF) ≥ 50% or within normal limits of the institution (only for subjects treated with PLD).

Exclusion Criteria:

  • Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor.
  • Any of the following treatment interventions within the specified time frame prior to Cycle 1 Day 1:

    1. Major surgery within 28 days.
    2. Radiation therapy within 21 days.
    3. Autologous or allogeneic stem cell transplant within 3 months.
  • A serious illness or medical condition(s) including, but not limited to, the following:

    1. Brain metastases that require immediate treatment or are clinically or radiologically unstable.
    2. Leptomeningeal disease that requires or is anticipated to require immediate treatment.
    3. Myocardial impairment of any cause.
    4. Significant gastrointestinal abnormalities.
    5. Active or uncontrolled infection.
  • Unresolved toxicity of Grade > 1 attributed to any prior therapies (excluding Grade 2 neuropathy, alopecia or skin pigmentation).
  • Pregnant or lactating females (including the cessation of lactation) or females of childbearing potential who have a positive serum pregnancy test within 14 days prior to Cycle 1 Day 1.
  • Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
  • 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of > 450 msec, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
  • History or current evidence of congenital long QT syndrome.
  • Taking medications that lead to significant QT prolongation.
  • Administration of strong and moderate CYP3A4 inhibitors and inducers as well as strong and moderate P-glycoprotein (P-gp) inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04516447


Contacts
Layout table for location contacts
Contact: Project Director 8582634333 info@zenopharma.com

Locations
Layout table for location information
United States, Texas
Site 0103 Recruiting
Houston, Texas, United States, 77030
Australia, Queensland
Site 2707 Recruiting
South Brisbane, Queensland, Australia, 4101
Site 2708 Recruiting
Sunshine Coast, Queensland, Australia, 4556
Australia, Victoria
Site 2706 Recruiting
Melbourne, Victoria, Australia, 3144
Australia, Western Australia
Site 2705 Recruiting
Nedlands, Western Australia, Australia, 6009
Bosnia and Herzegovina
Site 1001 Recruiting
Banja Luka, Bosnia and Herzegovina, 78000
Site 1002 Recruiting
Sarajevo, Bosnia and Herzegovina, 71000
Bulgaria
Site 1202 Not yet recruiting
Panagyurishte, Bulgaria, 4500
Site 1201 Recruiting
Sofia, Bulgaria, 1632
Georgia
Site 1401 Not yet recruiting
Tbilisi, Georgia, 0112
Korea, Republic of
Site 2903 Not yet recruiting
Seoul, Korea, Republic of, 03080
Site 2904 Not yet recruiting
Seoul, Korea, Republic of, 05505
Serbia
Site 1902 Not yet recruiting
Belgrade, Serbia, 11080
Sponsors and Collaborators
K-Group Beta
Investigators
Layout table for investigator information
Study Director: Philippe Pultar, MD K-Group Beta
Layout table for additonal information
Responsible Party: K-Group Beta
ClinicalTrials.gov Identifier: NCT04516447    
Other Study ID Numbers: ZN-c3-002
First Posted: August 18, 2020    Key Record Dates
Last Update Posted: March 23, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by K-Group Beta:
Solid Tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Carboplatin
Doxorubicin
Liposomal doxorubicin
Antineoplastic Agents
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action